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Abstract
Background: Hammerhead ribozymes are RNA-based molecules which bind and cleave other
RNAs specifically. As such they have potential as laboratory reagents, diagnostics and therapeutics.
Despite having been extensively studied for 15 years or so, their wide application is hampered by
their instability in biological media, and by the poor translation of cleavage studies on short
substrates to long RNA molecules. This work describes a systematic study aimed at addressing
these two issues.
Results: A series of hammerhead ribozyme derivatives, varying in their hybridising arm length and
size of helix II, were tested in vitro for cleavage of RNA derived from the carbamoyl phosphate
synthetase II gene of Plasmodium falciparum. Against a 550-nt transcript the most efficient (t1/2 = 26
seconds) was a miniribozyme with helix II reduced to a single G-C base pair and with twelve
nucleotides in each hybridising arm. Miniribozymes of this general design were targeted to three
further sites, and they demonstrated exceptional cleavage activity. A series of chemically modified
derivatives was prepared and examined for cleavage activity and stability in human serum. One
derivative showed a 103-fold increase in serum stability and a doubling in cleavage efficiency
compared to the unmodified miniribozyme. A second was almost 104-fold more stable and only 7-
fold less active than the unmodified parent.
Conclusion: Hammerhead ribozyme derivatives in which helix II is reduced to a single G-C base
pair cleave long RNA substrates very efficiently in vitro. Using commonly available phosphoramidites
and reagents, two patterns of nucleotide substitution in this derivative were identified which
conferred both good cleavage activity against long RNA targets and good stability in human serum.
Background
Hammerhead ribozymes were discovered as self-cleaving
motifs in a number of small, circular, pathogenic RNAs in
plants [1-3]. Uhlenbeck [4] showed that the ribozyme was
able to act in a bimolecular fashion as a true enzyme, ie
each ribozyme was able to cleave multiple substrates.
Haseloff and Gerlach [5] divided the hammerhead into a
form in which the majority of the conserved nucleotides
were located on the enzyme strand, with the only
sequence requirements for the substrate being UH (H = A,
U or C) [6-8]. Since 1988 this configuration, as shown in
Figure 1, has been the paradigm for hammerhead
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ribozyme design. Hammerhead ribozymes are sequence-
specific RNA cleaving agents with the potential to control
the expression of genes by eliminating specific RNAs. This
can be achieved by expressing the ribozyme within the tar-
get cell or by delivering it to the cell as a preformed entity.
One of the difficulties associated with delivering pre-
formed ribozymes is their instability in vivo, since RNA is
degraded very rapidly by ribonucleases present in cells
and extracellular fluids. Significant segments of ribonucle-
otides in the hammerhead ribozyme can be replaced with
more nuclease-resistant analogues like DNA, phospho-
rothioate linkages, or 2' O-methyl analogues; however,
within the conserved core of the hammerhead, the major-
ity of ribonucleotides are sensitive to modification. Yang
et al [9] demonstrated that predominantly DNA ribozyme
analogues with at least 4 ribonucleotides (G5, G8, A9 and
A15.1  or G15.2  numbered according to [10]) displayed
measurable cleavage activity (albeit reduced 5000-fold).
Phosphorothioate modification of DNA hybridising arms
and three of the conserved pyrimidines (C3, U4 & U7)
resulted in significant increase in stability in human
serum with a 6-fold loss in cleavage activity [11]. In the
context of 2'-O-methyl substituted ribozyme analogues, at
least 5 unmodified ribonucleotides (G5, G8, A9, A15.1 and
G15.2) were required for activity [9]. Paolella et al [12]
identified a minimum set of 6 ribonucleotides, U4, G5, A6,
G8, G12 and A15.1, in the conserved domain in which sub-
stitution with 2' O-allyl ribonucleotides inhibited activity.
Eckstein's group [13,14] showed that good activity and
stability in foetal calf serum could be achieved with 2'-
amino-2'-deoxyuridines at U4 and U7, and 2'-fluoro-2'-
deoxycytidine at C3. Hammerheads in which helix II was
shortened to only two base pairs, and all the pyrimidines
were 2'-fluoro or 2'-methoxyethoxy derivatives except for
U4 and U7 which were 2'-amino-2'-deoxy, were only 2–3
fold less active than the unmodified parent hammerhead
[15], but showed a 104-fold increase in nuclease stability.
A study of the effects of various modified nucleotides on
stability and activity of the 2'-O-methyl-pyrimidine mod-
ified hammerhead found a number of modifications,
including 2'-amino-2'-deoxyuridine, 2'-O-methyl-urid-
ine, and 2'-C-allyl-uridine at positions U4 and U7, sup-
ported good rates of cleavage [16]. These modifications
result in a greater than 103-fold increase in stability in
human serum, while the addition of an inverted thymi-
dine at the 3' end of the oligonucleotide (a 3'-3' linkage)
further improved the stability by two orders of magnitude.
Our laboratory is interested in the relationship between
hammerhead design and reactivity. We have described a
number of ribozyme derivatives that appear to have
promise as RNA cleavage agents. Minizymes (Mz) possess
a non-base-pairing tetranucleotide linker in place of helix
II [17]. In general, such minizymes are less active than
Schematic representation of Mrz-12/12-A bound to substrate S-30 Figure 1
Schematic representation of Mrz-12/12-A bound to substrate S-30. Helices I and III are formed between the ribozyme and sub-
strate. The standard hammerhead (eg Rz-12/12) has a 4 base pair helix II in place of the single g-c pair in the miniribozyme. The 
minizyme (Mz-12/12) has no helix II, but has a loop sequence gtttt connecting bases A9 and G12. Upper-case letters represent 
ribonucleotides, and lower-case letters represent deoxyribonucleotides. Nucleotides which have been further modified in this 
study are shown in blue.BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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standard hammerheads, although in some instances they
show comparable cleavage rate constants [18,19].
Miniribozymes (Mrz) have a single G10.1–C11.1 base pair
joined by a flexible linker in place of helix-loop II [19].
Asymmetric hammerheads are those in which the 5'
hybridising arm is restricted to around 5 or 6 nucleotides;
this modification eliminates the decrease in cleavage rate
that occurs with standard hammerheads when the length
of helix I, formed upon binding the substrate, increases to
greater than about 6 base pairs [20,21]. The purpose of
this study was to investigate the ability of these various
derivatives to cleave an RNA molecule (sequence derived
from the mRNA of the cpsII gene of the Malaria-causing
organism Plasmodium falciparum [22]) in the context of
two substrates, a 30-mer and a 550-mer. Having opti-
mised the cleavage activity of the ribozyme, we planned to
chemically modify the nuclease sensitive RNA nucle-
otides, using readily available protected nucleoside phos-
phoramidites, to extend the life of the ribozyme in the
presence of human serum.
Results
Ribozyme design
The primary target site for cleavage in this study was a pre-
viously identified site [23] in the cps II mRNA [22] of Plas-
modium falciparum. The chosen target site, centred at
position 3733 in the nucleotide sequence (Genbank refer-
ence L32150), has the local sequence 5' UAA CUU AUC
AAG GUC* AAG AAC AUG AUG UUC 3', where the site
of cleavage is denoted by the asterisk. A number of
ribozyme designs were tested for their ability to cleave this
RNA sequence either as a short (30-mer) oligonucleotide
or in a transcribed RNA segment (550 nt). These designs
included standard hammerhead ribozymes (Rz) which
are defined as those with a helix II consisting of four base
pairs closed at the end with a four-nucleotide loop, min-
izymes (Mz) [17] which lack helix II and instead the two
segments of conserved nucleotides are linked between A9
and G12 with a non-base-paired linker (in this case con-
sisting of 5 nucleotides), and finally miniribozymes (Mrz)
[19] which have a single G-C base pair replacing helix II
and in this instance a linker sequence consisting of four
deoxythymidines. In this communication the core of each
ribozyme is flanked by hybridising arms composed of
DNA of various lengths, where the length is given in the
ribozyme's name (e.g. Rz-6/12 has 6 nt in its 5' hybridis-
ing arm and 12 nt in its 3' arm). Hammerhead-ribozyme
derivatives of these designs were tested for their ability to
cleave the 30-mer substrate at pH 7.6, 37°C and 10 mM
MgCl2 under pseudo first-order conditions with an excess
of ribozyme. Ribozyme concentrations ranged from 50
nM to 10 µM. Cleavage data fitted well to single exponen-
tial curves to yield observed rate constants which were
plotted against the ribozyme concentration in each exper-
iment to determine the apparent dissociation constant
("Kd") and the maximum cleavage rate constant (kmax) for
each ribozyme-substrate pair (Table 1). In terms of cata-
lytic efficiency, the most efficient ribozyme was the stand-
ard hammerhead Rz-12/12. Its efficiency is due to a very
low "Kd" of 7 nM, despite displaying a kmax some 5-fold
less than Mrz-12/12. The highest kmax was displayed by
Rz-6/12; however it had a "Kd" about 60-fold greater than
Rz-12/12.
The abilities of all the ribozymes to cleave the same target
in the context of transcribed RNA (550 nt) was also exam-
ined. Mrz-12/12, by virtue of only a modest decrease in
kmax, and marginal increase in "Kd", was by far the most
efficient of all the designs tested. In contrast Mrz-8/8, Rz-
12/12 and Rz-6/12 displayed "Kd"'s between 2 and 3 mM,
which, in the case of Rz-12/12, is an increase of about
400-fold. Interestingly the kmax values displayed by Rz-12/
12 and Rz-6/12 were within experimental error, and were
the same as displayed by Rz-12/12 for cleavage of the
short substrate.
Cleavage of other targets by the miniribozyme
We examined whether the effectiveness of the miniri-
bozyme design was limited to this target site.
Miniribozymes, with long (>10 nucleotides) hybridising
arms were designed to cleave RNAs of interest to other
projects in the laboratory. Tet Mrz was a 53-mer oligonu-
Table 1: Kinetic parameters for RNA/DNA unmodified hammerhead ribozyme derivatives.
Ribozyme S-30 S-550
kmax (min-1)" K d" nM kmax/"Kd" (min-1µM-1)k max (min-1)" K d" nM kmax/"Kd" (min-1µM-1)
Rz-12/12 0.8 ± 0.1 7 ± 12 114 ± 200 0.7 ± 0.1 2600 ± 900 0.3 ± .2
Mz-12/12 0.22 ± 0.08 31 ± 6 7 ± 4 0.12 ± 0.01 240 ± 50 0.5 ± .2
Mrz-8/8 0.56 ± 0.06 210 ± 80 2.7 ± 1.3 0.005 ± 0.001 2200 ± 500 0.002 ± .001
Mrz-12/12 4.2 ± 0.3 75 ± 30 56 ± 26 1.6 ± 0.1 120 ± 50 13 ± 6
Rz-6/12 9 ± 1 400 ± 200 22 ± 13 0.6 ± 0.1 2800 ± 900 0.2 ± .1
Cleavage conditions; 37°C, pH 7.6, 10 mM MgCl2, ribozyme is in large excess over RNA substrates S-30 (30 nt) and S-550 (550 nt).BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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cleotide with conserved bases of RNA and hybridising
arms and stem loop II composed of DNA. This Mrz, with
hybridising arms of 18 and 19 nucleotides, was targeted to
cleave the GUC triplet at position 60 of the Tetrahymena
IVS ribozyme [24]. It cleaved the 388-nt transcript, L-21
ScaI, with a rate constant of 4.0 ± 0.2 min-1 (t1/2 = 10 sec-
onds), to about 70%, at pH 7.6, 37°C and 10 mM MgCl2.
Another miniribozyme with 14-mer arms (HC Mrz), tar-
geting a segment of Hepatitis C polyprotein mRNA, was
tested against a synthetic 29-mer substrate. Under our
standard conditions about 70% of the substrate was
cleaved, and the cleavage rate (>5 min-1) was too fast to be
measured reliably. In contrast, the standard ribozyme HC
Rz cleaved 78% of the same substrate with a rate constant
of only 0.2 ± 0.02 min-1. Finally, PDGF MRz, with hybrid-
ising arms each of 10 ribonucleotides, was tested against
both 25-mer synthetic and 707-nt transcribed substrates.
Under standard conditions, the 25-mer was ~ 80%
cleaved with a rate constant > 5 min-1. Reducing the mag-
nesium ion concentration to 1 mM yielded a rate constant
of 2.8 min-1 and 63% cleavage for the 25-mer substrate,
and 1.6 min-1 and 45% cleavage for the 707-nt transcript.
Identification of nuclease susceptible sites in human serum
Mrz-12/12 was the most efficient cleaver of the 550-nt
cpsII RNA transcript and was used as the platform to test
the effect of chemical modification on cleavage activity
and nuclease stability. Firstly, the stability of unprotected
Mrz-12/12 in RPMI + 10% human serum was determined
using  32P 5'-end labelled ribozyme at 37°C (Figure 2).
Approximately 90% of the miniribozyme is degraded in
10 seconds, and no full-length material is observed after
10 minutes. Initially there are three main sites of cleavage,
at U4, U7 and C15.2. After 10 minutes, nearly all the end-
labelled material co-migrates with the band generated by
alkaline digestion at U4. That initial, major product has a
half-life of about two hours under these conditions, as it
is slowly converted to a product one nucleotide shorter, ie
its 3' end corresponds to C3 in the original miniribozyme.
Nuclease resistant modifications
Commercially available modified phosphoramidites were
used to generate hammerhead derivatives which were
expected to be protected from nuclease degradation. The
effect of the various modifications on the cleavage ability
are given in Table 2. In these experiments the concentra-
tion of the miniribozyme was fixed at 1 µM and the sub-
strate S-30 at 5 nM. The nucleotide most sensitive to
chemical modification was U4. All the 2' modifications
tested (amino, deoxythymidine, deoxyuridine, and O-
methyl, shown as D, F, G and H, respectively, in Table 2)
diminished activity by more than 10-fold. Only the pres-
ence of a phosphorothioate linkage between U4 and G5
preserved the activity of the unmodified ribozyme. The
ready availability of 2'-O-methyl phosphoramidites, cou-
pled with the previous demonstrations [9,16] of tolerance
to that modification at C3, U7 and C15.2, lead us to synthe-
sise Mrz-J, which we expected to have reasonable activity
and nuclease stability. Its cleavage rate constant was actu-
ally twice that observed for the unmodified ribozyme, and
its stability in serum was increased about 103-fold. The
kinetics of degradation in serum (Figure 3) were not
straight-forward, displaying a rapid initial decay of about
25% of the starting material, followed by an approxi-
mately first-order decay with a half-life around 30 min-
utes. This second phase accounted for approximately 50%
in the total starting material, ie  after about 4 hours
approximately 25% of the full-length material remained
intact and thereafter decayed only very slowly. There was
a single major product, corresponding to cleavage at U4,
observed over the six hours of the experiment.
The single degradation site in Mrz-J suggested that a more
robust modification at this position would have a signifi-
cant effect on its lifetime in serum. Mrz-12/12 K was syn-
thesised with a 2'-amino modification at the U4 position
and with a 2'-O-methyl modification at each of the three
other conserved pyrimidines. Protection of the 3' end was
omitted from Mrz-12/12 K because it did not appear to
contribute significantly to the stability observed in Mrz-
12/12 J. As expected, the cleavage activity of Mrz-12/12 K
was significantly reduced compared to Mrz-12/12 J (Table
2), but stability in serum was greatly improved with only
minor losses apparent after 5 hours incubation at 37°C
(Figure 4). Even after 24 hours in 10% serum, approxi-
mately 25% of the radioactivity co-migrated with the full-
length material, representing an almost 104-fold increase
in stability. Even in the absence of 3' terminal protection
there was no 3' exonuclease activity apparent. The amount
of 32P label appearing in the gel lanes remained relatively
constant throughout the experiment implying a lack of
significant phosphatase activity in the serum. The main
sites for degradation were the remaining unprotected
(purine) ribonucleotides.
The modifications to the conserved nucleotides in this
study were all made in the context of a miniribozyme.
Compared to a standard hammerhead, the catalytic
domain is expected to be more conformationally flexible,
and therefore it should not be assumed that all the
changes described here can be directly applied to standard
hammerheads with a helix II of four base-pairs. However,
as for the miniribozyme, a standard ribozyme containing
a 2'-amino modification at U4, was about 15-fold less
efficient at cleaving S-30, (kobs = 0.05 min-1, Rz-12/12-L,
Table 2), compared to the unmodified ribozyme (Rz-12/
12).BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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Discussion
Work in this laboratory [20,21] and elsewhere [25] has
demonstrated that the cleavage kinetics of any conven-
tional hammerhead ribozyme are significantly inhibited
when the length of helix I exceeds about 6 bp. This has
been ascribed to an interaction between helices I and II
which stabilises an inactive conformation [20]. The angle
between helices I and II changes with metal ion
Degradation of 5' end-labelled Mrz-12/12 A in RPMI + 10% human serum at 37°C Figure 2
Degradation of 5' end-labelled Mrz-12/12 A in RPMI + 10% human serum at 37°C. Time of incubation in indicated above each 
lane. OH-indicates an alkaline digest of the same material. FL indicates the position of the full-length miniribozyme. The position 
of the fragments terminating at each of the ribonucleotides is indicated by the letters adjacent to the alkaline digest.BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
Page 6 of 11
(page number not for citation purposes)
concentration [26], and we postulated that a similar
change was required for the transformation between more
and less active conformations of the ribozyme [20]. This
general model is supported by more recent observations
using a variety of techniques [27-31] which conclude that
the dominant ground-state conformation of the hammer-
head is inactive and is in equilibrium with the active form.
The results of the present study are in accord with these
conclusions.
It is commonly observed, for conventional hammerhead
ribozymes, that cleavage efficiencies for long transcripts
are about 2 orders of magnitude lower than for short sub-
strates [32]. This has been observed here also for ribozyme
derivatives of both the conventional design and of the
short-armed (8-nt) miniribozyme (Table 1). In these cases
the cause appears to reside largely in the apparent dissoci-
ation constant "Kd". In contrast, the longer-armed miniri-
bozyme (Mrz-12/12) shows excellent cleavage kinetics
against both short and long substrates. It appears that the
more flexible miniribozyme is better suited to binding to
the target in the context of a long RNA. These data can be
interpreted according to a simple model in which
ribozymes possessing a stable helix II form a more rigid
three-dimensional structure [33,34] which does not bind
strongly to the long, folded substrate. When binding is
achieved at very high ribozyme concentrations, the
ribozyme-substrate complex is sterically hindered to such
an extent that the complex is locked into a poorly active
conformation. Hence Rz-6/12 and Rz-12/12 display simi-
lar maximal rate constants. In contrast, the Mrz lacking
helix II is more flexible and readily adapts to binding the
folded substrate with relatively minor effects on kobs and
"Kd". This observation is not specific to target or cleavage
triplet, since four unrelated targets, including three long
transcripts, one with an AUC cleavage triplet, were cleaved
with rate constants much higher than typically reported
for cleavage even of short substrates. It is worth noting the
magnitude of the observed cleavage rate constants; under
our standard conditions these miniribozymes cleave their
targets with half-lives in the range of < 5 to 25 seconds.
The unmodified Mrz-12/12 was very unstable in 10%
human serum. Degradation occurred by endonucleolytic
cleavage at the 3' side of pyrimidine nucleotides. Since the
hybridising arms and helix-loop II are composed of DNA,
the four remaining ribo-pyrimidine nucleotides in the
conserved domain were the critical residues for stabilisa-
tion. Modification of all four ribopyrimidines with 2'-
aminouridine and 2'-fluorocytidine, (Mrz-12/12 B),
resulted in a more than 10-fold decrease in maximum
cleavage rate constant. This contrasts with some previous
results where a U4, U7-amino derivatised ribozyme with a
standard helix II was only marginally diminished in activ-
ity [14], and a U4, U7-amino derivatised ribozyme [16], in
which all the remaining pyrimidines were modified with
2'-O-methyl groups, was only two-fold less active than the
parent ribozyme. The study by Heidenreich et al [14] was
confounded by the fact that the cleavage kinetics were
measured against a long transcript and are relatively slow
compared with rates typically observed for short sub-
strates, and therefore it seems likely that access to the tran-
script, rather than chemistry of cleavage, may have been
rate determining in that case. In a later report [15], a mod-
ification pattern identical to miniribozyme B (ie C3, C15.2-
fluoro and U4, U7-amino) but in a ribozyme with a
Table 2: Cleavage Rate constants for cleavage of S-30 by Chemically Modified Mrz-12/12.
Miniribozyme 
(Mrz-12/12)





A----- 4 . 2  ±  0 . 3 1
BF N H 2 NH2 F - 0.30 ± 0.05 -
C- N H 2 NH2 - - 0.18 ± 0.01 -
D- N H 2 - - - 0.30 ± 0.03 -
E-- N H 2 - - 7.7 ± 0.8 -
F - dT - - - 0.014 ± 0.005 -
G - dU - - - 0.024 ± 0.007 -
H - OMe - - - 0.01 ± 0.007 -
I - ps - - - 3.9 ± 0.06 -
J OMe ps OMe OMe psps 7.3 ± 0.7 1400
K OMe NH2 OMe OMe - 0.6 ± 0.1 8600
Rz-12/12-L - NH2 - - - 0.05 ± 0.009 -
Cleavage conditions; 37°C, pH 7.6, 10 mM MgCl2. [Rz] = 1 µM, [S30] = 5 nM. (- = unmodified, ie 2'OH). F = 2'-fluoro, NH2 = 2'-amino, dT = 2'-
deoxythymidine, dU = 2'-deoxyuridine, OMe = 2'-O-methyl, ps = 3' phosphorothioate linkage. Stability is defined as the time required in 10% 
human serum to degrade 75% of full-length ribozyme, relative to unmodified miniribozyme A.BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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Degradation of Mrz-12/12 J in RPMI + 10% Human Serum Figure 3
Degradation of Mrz-12/12 J in RPMI + 10% Human Serum. Experimental conditions are as described in Figure 2.BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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Degradation of Mrz-12/12 K in RPMI + 10% Human Serum, and by alkaline digest Figure 4
Degradation of Mrz-12/12 K in RPMI + 10% Human Serum, and by alkaline digest. Experimental conditions are as described in 
Figure 2.BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
Page 9 of 11
(page number not for citation purposes)
standard helix II resulted in a more than 10-fold loss in
turnover number (kcat). The series of singly and doubly
substituted miniribozymes (C-E) showed clearly that a 2'-
aminouridine at position 4 was solely responsible for the
loss in activity. This is consistent with the result of Beigel-
man et al [16], but, in contrast to that result, the cleavage
activity of the miniribozyme was not rescued by the addi-
tion of an amino group at U7. A phosphorothioate linkage
between U4 and G5 (Mrz-12/12 I) was the only modifica-
tion tested here that did not suppress cleavage activity.
This is in accord with interference studies [35,36] identi-
fying U4 as insensitive to phosphorothioate modification.
The results for dU and 2'O-methyl substitutions contrast
with Beigelman et al [16] where, in a background of 2'O-
methyl-pyrimidines, the effect of those substitutions at U4
were relatively minor.
In serum, Mrz-12/12 J was degraded by cleavage at the U4
phosphorothioate, where an initial, quite rapid degrada-
tion was followed by a slower step which is not complete
at 6 hours. Chemically synthesised phosphorothioate
linkages are a mixture of two enantiomers and it is likely
that the multiphase kinetics observed were due in part to
the different susceptibility of the two isomers (Rp and Sp)
to the nucleases present in the serum [37,38]. Mrz12/12 K
has 2'-amino modification at U4, is very stable in serum,
and is only 7-fold less active than the unmodified parent.
The products of nuclease cleavage of Mrz-12/12 K indicate
that degradation occurred by cleavage at the unprotected
ribopurine sites. This derivative was not protected at the 3'
terminus, but unlike earlier work [11,16,38], there was no
evidence in this experiment for 3'-DNA exonuclease
activity.
In recent times RNAi has surplanted catalytic RNA as the
method of choice for suppression of gene expression in
many eukaryotic cells [39]. Results published to date sug-
gest that it may be effective in many settings, including
possibly as a therapeutic. However, the mechanistic
details of RNAi activity are quite complex and are still
being unravelled, and it seems likely that there will be cell
types, perhaps whole classes of organisms, that lack the
necessary cellular machinery. For this reason, it may be
premature to abandon the autonomous catalytic RNAs.
During the 1990's, many studies aiming to demonstrate
hammerhead ribozymes as gene silencing agents in vivo
were not successful. The results obtained here, and in
other recent studies on the effect of non-conserved
sequences on the kinetics of cleavage [25,40,41], are
beginning to reveal shortcomings of many studies of that
era. That is the in vivo catalytic efficiency of the hammer-
heads under study was compromised by their simplistic
design, which was based on in vitro studies performed
with very short substrates. We were too quick to ascribe
poor cleavage of transcripts to "accessibility" issues, and
too slow to undertake comprehensive studies to under-
stand the phenomenon. The miniribozyme design, and
the effective nuclease protection afforded by the simple
chemical modifications described here, provide an
opportunity to revisit cellular and in vivo experiments with
hammerheads that are around two orders of magnitude
more efficient.
Conclusions
Long RNA substrates are much more effectively cleaved by
miniribozymes than similarly targeted standard hammer-
heads. The presence of a stable helix II in the standard
hammerhead appears to inhibit binding of the ribozyme
to the substrate, and prevent the conformational mobility
required for activity. Miniribozymes are affected by serum
nucleases in a similar way to standard hammerheads, with
cleavage occurring at the 3' side of unprotected ribopyri-
midines. This work shows that it is readily possible to
modify RNA/DNA hammerhead ribozymes, using com-
mercially available reagents, to yield greatly improved
nuclease resistance and retention of significant cleavage
activity. These modified miniribozymes represent excel-
lent candidates for cellular and in vivo studies on suppres-
sion of gene expression.
Methods
Oligonucleotide synthesis
Oligoribonucleotides were synthesised using DNA phos-
phoramidites and ancillary reagents supplied by Perkin
Elmer (Applied Biosystems Division, Foster City, CA),
RNA and modified phosphoramidites from Glen Research
(Sterling, VA) and using an Applied Biosystems Model
394 DNA synthesiser. Phosphorothioates were intro-
duced by oxidation with Beaucage reagent (Glen
Research, Sterling, VA). Deprotection and purification of
oligonucleotides were as described previously [20]. The
purity of each oligonucleotide was checked by labelling its
5'-end with 32P phosphate using T4 polynucleotide kinase
(New England Biolabs, Beverly, MA, USA) and [γ-32P]-ATP
(Du Pont, Wilmington, DE), followed by electrophoresis
in a 15% polyacrylamide gel containing 7 M urea and vis-
ualisation using a Molecular Dynamics PhosphorImaging
system (Sunnyvale, CA). The concentrations of the puri-
fied oligonucleotides were determined by UV spectros-
copy using the following molar extinction coefficients for
the various nucleotides at 260 nm: A, 15.4 × 103; G, 11.7
× 103; C, 7.3 × 103; T/U, 8.8 × 103 l mol-1 cm-1. All oligo-
nucleotides were stored in distilled, deionised and auto-
claved water at -20°C.
The 550-nt CPSII substrate was transcribed by T7 RNA
polymerase from the vector pCPS3b.1 [22] after linearisa-
tion with Eco RI restriction enzyme using an Ampliscribe
T7 kit (Epicentre Technologies, Madison, WI, USA). The
transcription reaction contained CTP, GTP and ATP (unla-BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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belled) at 5 mM, UTP at 0.5 mM and 32P UTP at about 1
nM. The transcription was for 90 minutes at 37°C, fol-
lowed by the addition of 0.5 µL of DNAaseI and incuba-
tion for a further 20 minutes. The mixture was extracted
three times with a 1:1 phenol/chloroform mix and once
with chloroform, before precipitation of the transcript by
the addition of 1/3 volume of 7.5 M ammonium acetate
and incubation on ice for at least 2 hours. After recovery
of the transcript by centrifugation and washing, the degree
of incorporation of 32P-labelled uridine was measured by
Cerenkov counting of the transcript and the unincorpo-
rated UTP. The Tetrahymena intervening sequence tran-
script was generated from the ScaI digested pT7L-21 vector
[24] (ATCC 40291) using the same method. The PDGF
transcript was generated by T3 RNA polymerase
transcription from the Eco RI digested vector pBSPDGF-
LA using an Ampliscribe T3 kit (Epicentre Technologies,
Madison, WI, USA). The vector pBSPDGF-LA was gener-
ated by insertion of the Xba I/Eco RI fragment from
pmetPDGF-LA [42] into a similarly digested pBluescribe
vector.
Oligonucleotide sequences
Deoxyribonucleotides are denoted by lower case letters,
ribonucleotides by uppercase letters, modified nucle-
otides are shown in bold, Cf = 2'-fluoro-2'-deoxycytidine,
Cme = 2' O-methylcytidine, Uam = 2'-deoxy-2'-aminourid-
ine, Ume = 2' O-methyluridine, ps  = phosphorothioate
linkage. S-30, UAA CUU AUC AAG GUC* AAG AAC AUG
AUG UUc, * denotes site of cleavage; Mrz-8/8, atgttctt
CUGAUGA gttttc GAAAC cttgat; Mrz-12/12, catcatgttctt
CUGAUGA gttttc GAAAC cttgataagt; Mz-12/12 catcatgttctt
CUGAUGA gtttt GAAAC cttgataagt; Rz-12/12, catcatgttctt
CUGAUGA GUCC UUUU GGAC GAAAC cttgataagt; Rz-
6/12, gttctt CUGAUGA GUCC UUUU GGAC GAAAC ctt-
gataagt; Mrz-12/12-A (= Mrz-12/12), catcatgttctt
CUGAUGA gttttc GAAAC cttgataagt; Mrz-12/12-B, catcat-
gttctt CfUamGAUamGA gttttc GAAACf cttgataagt; Mrz-12/
12-C, catcatgttctt CUamGAUamGA gttttc GAAAC cttgataagt;
Mrz-12/12-D, catcatgttctt CUamGAUGA gttttc GAAAC ctt-
gataagt; Mrz-12/12-E, catcatgttctt CUGAUamGA gttttc
GAAAC cttgataagt; Mrz-12/12-F, catcatgttctt CtGAUGA
gttttc GAAAC cttgataagt; Mrz-12/12-G, catcatgttctt
CuGAUGA gttttc GAAAC cttgataagt; Mrz-12/12-H, catcat-
gttctt CUmeGAUGA gttttc GAAAC cttgataagt; Mrz-12/12-I,
catcatgttctt CUpsGAUGA gttttc GAAAC cttgataagt; Mrz-
12/12-J, catcatgttctt CmeUpsGAUmeGA gttttc GAAACme ctt-
gataagtpstpst; Mrz-12/12-K, catcatgttctt CmeUam-
GAUmeGA gttttc GAAACme  cttgataagt; Rz-12/12-L,
catcatgttctt CUamGAUGA GUCC UUUU GGAC GAAAC
cttgataagt; Tet Mrz, gcaatctattggtttaaa CUGAUGA gttttc
GAAAC tagctaccaggtgcatg 3'; HC Mrz, 5' gtcgccacgacgac
CUGAUGA gttttc GAAAC gttcccgctggt 3'; HC Rz, 5'
gtcgccacgacgac CUGAUGA GGCC GAAA GGCC GAAAC
gttcccgctggt 3'; HC S29, 5' ACCAGCG-
GGAACGUCGUCGUCGUGGCGAc 3'; PDGF Mrz, 5'
CAGCUUCCUC CUGAUGA ggtaac GAAAU GCUUCUCt
3' ; PDGF S25, 5' GAAGAGAAGCAUCGAGGAAGCUGUc
3'.
Cleavage kinetics
Cleavage kinetics were studied at 37°C, pH 7.6 and 10
mM MgCl2 under conditions of ribozyme excess; the sub-
strate concentrations varied between 4 and 20 nM, and
the ribozyme concentrations were between 20 nM and 10
µM. The short, synthetic substrates were labelled at their
5' ends using polynucleotide kinase (Roche Molecular
Biochemicals) and γ-32P ATP. The long, transcribed sub-
strates were uniformly labelled by including α-32P UTP in
the transcription reaction. The ribozymes and 32P-labelled
substrates were mixed together in 20 µL of 50 mM Tris
buffer and heated to 85°C for two minutes, then incu-
bated at 37°C for 2 minutes. The tube containing the mix
was centrifuged, and 2 µL was removed and put into 4 µL
quenching solution which contained 90% formamide, 20
mM EDTA and 0.01 % xylene cyanol and bromophenol
blue. The reaction was initiated by the addition of 2 µL of
100 mM MgCl2, and 2 µL samples were removed at vari-
ous times and quenched as described above. The reaction
products were separated using 15% denaturing polyacry-
lamide gels (containing 7 M urea), and then imaged using
a Molecular Dynamics PhosphorImager. At each time-
point, the amount of the substrate cleaved was calculated
and plotted versus time. The data were fitted by a least-
squares method using the program MacCurveFit [43], to
an equation of the form: Pt = P∞-(exp(-kobst)P∆) where Pt
is the amount of product at time t, P∞ is amount of prod-
uct generated in the exponential phase of the reaction, kobs
is the first-order rate constant for the reaction, and P∆ is
the difference in the amount of product at t = 0 and P∞.
Some reactions resulted in biphasic kinetics in which the
first-order phase described above was followed by a
slower step which was accommodated adequately in the
curve-fitting process by the addition of a linear term, Pt =
{P∞-(exp(-kobst)P∆)} + d*t. Apparent dissociation con-
stants "Kd" and the maximal first-order rate constants kmax
were determined from the plot of kobs versus ribozyme
concentration according to the simple binding isotherm:
kmax = (kobs * [Rz])/("Kd" + [Rz]) by least-squares fitting
using the program MacCurveFit.
Serum stability
Ribozymes labelled at their 5' end with 32P phosphate
were dissolved in RPMI medium (Gibco) at 2 µM and the
reactions were initiated by adding human serum (pooled
human serum, Red Cross Blood Bank, Sydney, NSW), to a
final concentration of 10%. A 2 µL sample was removed
immediately and the remainder incubated at 37°C with
samples removed at the times indicated in Figures 2,3,4.
The samples were quenched by addition to 4 µL of 90%BMC Chemical Biology 2004, 4:1 http://www.biomedcentral.com/1472-6769/4/1
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formamide containing 20 mM EDTA and 0.01%
bromophenol blue and xylene cyanol. The products of
nuclease digestion in each sample were separated on 15%
polyacrylamide gels containing 7 M urea and imaged
using a Molecular Dynamics PhosphorImager.
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